newsfilter
← Latest News
Business Wire·

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Affirms expectations for initial topline results in 1H 2022 Recent FDA pre-IND meeting provides valuable guidance on U.S. regulatory path; company expects to submit IND in 1Q 2022 Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage bioph